HUTCHMED (China) Limited (0013.HK)
HKD 23.0
(-0.22%)
HKD 23.0
(-0.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 151.55 Million USD | 293.35% |
| 2022 | 115.3 Million USD | 17.79% |
| 2021 | 97.89 Million USD | 148.1% |
| 2020 | 39.45 Million USD | -11.8% |
| 2019 | 44.73 Million USD | -36.24% |
| 2018 | 70.16 Million USD | 7.31% |
| 2017 | 65.38 Million USD | 9.42% |
| 2016 | 59.75 Million USD | -11.38% |
| 2015 | 67.42 Million USD | 241.16% |
| 2014 | 19.76 Million USD | -16.83% |
| 2013 | 23.76 Million USD | -75.25% |
| 2012 | 95.99 Million USD | 3.48% |
| 2011 | 92.76 Million USD | 16.15% |
| 2010 | 79.86 Million USD | 20.26% |
| 2009 | 66.41 Million USD | 30.62% |
| 2008 | 50.84 Million USD | 35.75% |
| 2007 | 37.45 Million USD | 28.65% |
| 2006 | 29.11 Million USD | 25.24% |
| 2005 | 23.24 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 62.77 Million USD | 542.59% |
| 2024 Q2 | 62.77 Million USD | 0.0% |
| 2023 Q1 | 89.95 Million USD | 216.39% |
| 2023 FY | 453.55 Million USD | 293.35% |
| 2023 Q4 | -14.18 Million USD | 0.0% |
| 2023 Q3 | -14.18 Million USD | -115.77% |
| 2023 Q2 | 89.95 Million USD | 0.0% |
| 2022 Q2 | -58.5 Million USD | 0.0% |
| 2022 Q3 | -77.28 Million USD | -32.1% |
| 2022 FY | 115.3 Million USD | 17.79% |
| 2022 Q4 | -77.28 Million USD | 0.0% |
| 2022 Q1 | -58.5 Million USD | -4.24% |
| 2021 Q4 | -56.12 Million USD | 0.0% |
| 2021 Q3 | -56.12 Million USD | -420.78% |
| 2021 FY | 97.89 Million USD | 148.1% |
| 2021 Q2 | 17.49 Million USD | 5.3% |
| 2021 Q1 | 16.61 Million USD | 139.31% |
| 2020 Q3 | -42.26 Million USD | -427.34% |
| 2020 FY | 39.45 Million USD | -11.8% |
| 2020 Q1 | 10.28 Million USD | 137.45% |
| 2020 Q2 | 12.91 Million USD | 25.61% |
| 2020 Q4 | -42.26 Million USD | 0.0% |
| 2019 Q2 | 12.39 Million USD | 10.55% |
| 2019 Q1 | 11.21 Million USD | 200.57% |
| 2019 FY | 44.73 Million USD | -36.24% |
| 2019 Q4 | -27.45 Million USD | -35.09% |
| 2019 Q3 | -20.32 Million USD | -263.95% |
| 2018 Q3 | -3.1 Million USD | -120.66% |
| 2018 FY | 70.16 Million USD | 7.31% |
| 2018 Q2 | 15.03 Million USD | -1.64% |
| 2018 Q1 | 15.28 Million USD | 293.79% |
| 2018 Q4 | -11.14 Million USD | -259.07% |
| 2017 FY | 65.38 Million USD | 9.42% |
| 2017 Q4 | -7.88 Million USD | 0.0% |
| 2017 Q1 | 2.81 Million USD | 156.5% |
| 2017 Q3 | -7.88 Million USD | -380.07% |
| 2017 Q2 | 2.81 Million USD | 0.0% |
| 2016 FY | 59.75 Million USD | -11.38% |
| 2016 Q4 | -4.98 Million USD | 0.0% |
| 2016 Q3 | -4.98 Million USD | -450.05% |
| 2016 Q2 | 1.42 Million USD | 0.0% |
| 2016 Q1 | 1.42 Million USD | -94.27% |
| 2015 Q1 | 5.64 Million USD | 445.05% |
| 2015 FY | 67.42 Million USD | 241.16% |
| 2015 Q4 | 24.84 Million USD | -27.53% |
| 2015 Q3 | 34.28 Million USD | 507.66% |
| 2015 Q2 | 5.64 Million USD | 0.0% |
| 2014 Q2 | 4.5 Million USD | 0.0% |
| 2014 Q1 | 4.5 Million USD | 132.65% |
| 2014 Q4 | -1.63 Million USD | -113.2% |
| 2014 FY | 19.76 Million USD | -16.83% |
| 2014 Q3 | 12.39 Million USD | 175.06% |
| 2013 Q1 | 4.53 Million USD | 81.05% |
| 2013 Q2 | 4.53 Million USD | 0.0% |
| 2013 Q3 | 7.34 Million USD | 61.87% |
| 2013 Q4 | -13.79 Million USD | -287.85% |
| 2013 FY | 23.76 Million USD | -75.25% |
| 2012 FY | 95.99 Million USD | 3.48% |
| 2012 Q4 | 2.5 Million USD | 0.0% |
| 2012 Q3 | 2.5 Million USD | 0.0% |
| 2011 FY | 92.76 Million USD | 16.15% |
| 2010 FY | 79.86 Million USD | 20.26% |
| 2009 FY | 66.41 Million USD | 30.62% |
| 2008 FY | 50.84 Million USD | 35.75% |
| 2007 FY | 37.45 Million USD | 28.65% |
| 2006 FY | 29.11 Million USD | 25.24% |
| 2005 FY | 23.24 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | 9.487% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 97.677% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -426.603% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | 61.614% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 525.669% |
| Lee's Pharmaceutical Holdings Limited | 551.31 Million HKD | 72.511% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 90.155% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | 67.844% |
| PuraPharm Corporation Limited | 216.62 Million HKD | 30.041% |
| SSY Group Limited | 3.48 Billion HKD | 95.657% |
| JBM (Healthcare) Limited | 319.41 Million HKD | 52.554% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 75.575% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 99.651% |